Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Cai, J ^a   Yang, C ^a   Yang, Q ^a   Ding, H ^a   Jia, J ^a   Guo, J ^a   Wang, J ^a   Wang, Z ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Agomir; Cisplatin; Epithelial ovarian cancer; Let 7e; Methylation

Indexed keywords

CISPLATIN; DNA; LET 7E PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CARCINOMA; PLASMID; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

EID: 84886997199     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.39     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. (Pubitemid 46148091)
2. Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 2009; 12: 114-126.
3. Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat 2002; 5: 147-161. (Pubitemid 35033806)
4. Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 2003; 6: 169-172. (Pubitemid 37129916)
5. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279. (Pubitemid 37487159)
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
7. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004; 18: 504-511. (Pubitemid 38372808)
8. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67: 11612-11620.
9. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756. (Pubitemid 38697282)
10. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, IeM Shih, Zhang Y et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008; 3: e2436.
11. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27: 1788-1793. (Pubitemid 351380263)
12. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010; 17: 523-531.
13. Miller TE, Ghoshal K, Ramaswamy B. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283: 29897-29903.
14. Li Y, VandenBoom 2nd TG, Kong D, Wang Z, Ali S, Philip PA et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712.
15. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008; 111: 478-486.
16. Wu M, Jolicoeur N, Li Z, Zhang L, Fortin Y, L'Abbe D et al. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 2008; 29: 1710-1716.
17. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798. (Pubitemid 38058492)
18. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet. 2005; 37: 495-500. (Pubitemid 40617277)
19. Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 2010; 10: 788-795.
20. Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol 2010; 176: 2607-2615.
21. Ehlén A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med 2010; 8: 78.
22. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67: 11111-11116. (Pubitemid 350248533)
23. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1-9.
24. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 2007; 282: 8256-8264. (Pubitemid 47093612)
25. Rossi S, Sevignani C, Nnadi SC, Siracusa LD, Calin GA. Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. Mamm Genome 2008; 19: 526-540.
26. Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009; 69: 9038-9046.
27. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008; 68: 4123-4132.
28. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012; 3: 1011-1025.
29. Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D et al. DNA methylation- regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 2012; 287: 5639-5649.
30. Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L et al. Loss of let-7 upregulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 2012; 7: e33729.
31. Ewen ME, Lamb J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 2004; 10: 158-162. (Pubitemid 38410973)
32. Biliran Jr H, Wang Y, Banerjee S, Xu H, Heng H, Thakur A et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 2005; 11: 6075-6086. (Pubitemid 41170340)
33. Warenius HM, Seabra LA, Maw P. Sensitivity to cis- diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int J Cancer 1996; 67: 224-231. (Pubitemid 26274154)
34. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010; 17: 574-583.
35. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 2006; 70: 1390-1394. (Pubitemid 44435991)
36. Blair BG, Larson CA, Safaei R, Howell SB. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin Cancer Res 2009; 15: 4312-4321.
37. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002; 62: 6559-6565. (Pubitemid 35364122)
38. Safaei R, Otani S, Larson BJ, Rasmussen ML, Howell SB. Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol 2008; 73: 461-468. (Pubitemid 351159216)
39. Shahzad MM, Lopez-Berestein G, Sood AK. Novel strategies for reversing platinum resistance. Drug Resist Updat 2009; 12: 148-152.
40. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987; 47: 414-418. (Pubitemid 17009602)
41. -ΔΔCT method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
42. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007; 67: 10117-10122. (Pubitemid 350070782)